Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary

References

• HarrisSTReginsterJYHarleyCRisk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture studyBone200944575876519168160
   PubMed Web of Science ®Google Scholar
• RingeJDDohertyJGAbsolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treatRheumatol Int201030786386920035331
   PubMed Web of Science ®Google Scholar
• StevensonMJonesMLde NigrisEBrewerNDavisSOakleyJA systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosisHealth Technol Assess2005922116015929857
   PubMed Web of Science ®Google Scholar
• WattsNBDiabDLLong-term use of bisphosphonates in osteoporosisJ Clin Endocrinol Metab20109541555156520173017
   PubMed Web of Science ®Google Scholar
• BorgstromFStromOCoelhoJThe cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAXOsteoporos Int201021349550519565175
   PubMed Web of Science ®Google Scholar
• KanisJAAdamsJBorgstromFThe cost-effectiveness of alendronate in the management of osteoporosisBone200842141518156107
   PubMed Web of Science ®Google Scholar
• TostesonANMeltonLJ3rdDawson-HughesBCost-effective osteoporosis treatment thresholds: the United States perspectiveOsteoporos Int200819443744718292976
   PubMed Web of Science ®Google Scholar
• MeltonLJ3rdKanisJAJohnellOPotential impact of osteoporosis treatment on hip fracture trendsJ Bone Miner Res200520689589715883627
   PubMed Web of Science ®Google Scholar
• FeldsteinACWeyckerDNicholsGAEffectiveness of bisphosphonate therapy in a community settingBone200944115315918926939
   PubMed Web of Science ®Google Scholar
• CrillyRGHillierLMMasonMGutmanisICoxLPrevention of hip fractures in long-term care: relevance of community-derived dataJ Am Geriatr Soc201058473874520345863
   PubMed Web of Science ®Google Scholar
• JaglalSBWellerIMamdaniMPopulation trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong?J Bone Miner Res200520689890515883628
   PubMed Web of Science ®Google Scholar
• SirisESHarrisSTRosenCJAdherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databasesMayo Clin Proc20068181013102216901023
   PubMed Web of Science ®Google Scholar
• FisherAAO’BrienEDDavisMWTrends in hip fracture epidemiology in Australia: possible impact of bisphosphonates and hormone replacement therapyBone200945224625319409518
   PubMed Web of Science ®Google Scholar
• KhoslaSBurrDCauleyJBisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res200722101479149117663640
   PubMed Web of Science ®Google Scholar
• PazianasMMillerPBlumentalsWABernalMKothawalaPA review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristicsClin Ther20072981548155817919538
   PubMed Web of Science ®Google Scholar
• AbrahamsenBBisphosphonate adverse effects, lessons from large databasesCurr Opin Rheumatol201022440440920473174
   PubMed Web of Science ®Google Scholar
• LoJCO’RyanFSGordonNPPrevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposureJ Oral Maxillofac Surg201068224325319772941
   PubMed Web of Science ®Google Scholar
• PazianasMCooperCEbetinoFHRussellRGLong-term treatment with bisphosphonates and their safety in postmenopausal osteoporosisTher Clin Risk Manag2010632534320668715
   PubMed Web of Science ®Google Scholar
• KhanAASandorGKDoreEBisphosphonate associated osteonecrosis of the jawJ Rheumatol200936347849019286860
   PubMed Web of Science ®Google Scholar
• MavrokokkiTChengASteinBGossANature and frequency of bisphosphonate-associated osteonecrosis of the jaws in AustraliaJ Oral Maxillofac Surg200765341542317307586
   PubMed Web of Science ®Google Scholar
• WalterCAl-NawasBFrickhofenNPrevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patientsHead Face Med201061120615236
   PubMed Web of Science ®Google Scholar
• WooSBHellsteinJWKalmarJRNarrative [corrected] review: bisphosphonates and osteonecrosis of the jawsAnn Intern Med20061441075376116702591
   PubMed Web of Science ®Google Scholar
• KhanAASandorGKDoreECanadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jawJ Rheumatol20083571391139718528958
   PubMed Web of Science ®Google Scholar
• RizzoliRBurletNCahallDOsteonecrosis of the jaw and bisphosphonate treatment for osteoporosisBone200842584184718314405
   PubMed Web of Science ®Google Scholar
• SambrookPNEbelingPOsteonecrosis of the jawCurr Rheumatol Rep20081029710118460263
   PubMedGoogle Scholar
• SilvermanSLLandesbergROsteonecrosis of the jaw and the role of bisphosphonates: a critical reviewAm J Med2009122Suppl 2S33S4519187811
   PubMed Web of Science ®Google Scholar
• Australian Bureau of StatisticsAustralian Demographic Statistics: Population Projections Catalogue No 3101.0Canberra (ACT)Australian Bureau of Statistics2009
   Google Scholar
• Medicare AustraliaPBS Statistics2010 Available from: http://www.medicareaustralia.gov.au/provider/pbs/stats.jsp. Accessed 2010 Oct 29.
   Google Scholar
• DeeksEDDhillonSSpotlight on strontium ranelate: in postmenopausal osteoporosisDrugs Aging201027977177320809666
   PubMed Web of Science ®Google Scholar
• MariePJFelsenbergDBrandiMLHow strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosisOsteoporos Int201092 [Epub ahead of print]
   Google Scholar
• GennariLMerlottiDNutiRSelective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifeneClin Interv Aging20105192920169039
   PubMed Web of Science ®Google Scholar
• KungAWChuEYXuLBazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosisExpert Opin Pharmacother20091081377138519445558
   PubMed Web of Science ®Google Scholar
• CanalisEUpdate in new anabolic therapies for osteoporosisJ Clin Endocrinol Metab20109541496150420375217
   PubMed Web of Science ®Google Scholar
• DealCFuture therapeutic targets in osteoporosisCurr Opin Rheumatol200921438038519461517
   PubMed Web of Science ®Google Scholar
• FabbricianiGPirroMManfredelliMRTransient osteoporosis of the hip: successful treatment with teriparatideRheumatol Int2010318 [Epub ahead of print]
   Google Scholar
• LiXWarmingtonKSNiuQTInhibition of sclerostin by monoclonal antibody increases bone formation, bone mass and bone strength in aged male ratsJ Bone Miner Res2010716 [Epub ahead of print]
   Google Scholar
• JulesJAshleyJWFengXSelective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosisExpert Opin Ther Targets201014992393420678025
   PubMed Web of Science ®Google Scholar
• PalaniswamyCSelvarajDRRaoVPatelUNewer therapies for osteoporosisAm J Ther201017219720020305400
   PubMed Web of Science ®Google Scholar
• RouxSNew treatment targets in osteoporosisJoint Bone Spine201077322222820381400
   PubMed Web of Science ®Google Scholar
• InderjeethCAFooACLaiMMGlendenningPEfficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidenceBone200944574475119130909
   PubMed Web of Science ®Google Scholar
• Salari SharifPAbdollahiMLarijaniBCurrent, new and future treatments of osteoporosisRheumatol Int2010730 [Epub ahead of print]
   Google Scholar
• LibermanUAHochbergMCGeusensPHip and non-spine fracture risk reductions differ among antiresorptive agents: evidence from randomised controlled trialsInt J Clin Pract200660111394140017026515
   PubMed Web of Science ®Google Scholar
• AbelsonARingeJDGoldDTLangeJLThomasTLongitudinal change in clinical fracture incidence after initiation of bisphosphonatesOsteoporos Int20102161021102919722103
   PubMed Web of Science ®Google Scholar
• Le GoffBGuillotPGlemarecJBerthelotJMMaugarsYA comparison between bisphosphonates and other treatments for osteoporosisCurr Pharm Des201016273037304420722614
   PubMed Web of Science ®Google Scholar
• MacLeanCNewberrySMaglioneMSystematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosisAnn Intern Med2008148319721318087050
   PubMed Web of Science ®Google Scholar
• MasudTMcClungMGeusensPReducing hip fracture risk with risedronate in elderly women with established osteoporosisClin Interv Aging2009444544919966913
   PubMed Web of Science ®Google Scholar
• FeldsteinACNicholsGOrwollEThe near absence of osteoporosis treatment in older men with fracturesOsteoporos Int200516895396215928798
   PubMed Web of Science ®Google Scholar
• PapaioannouAKennedyCCIoannidisGThe osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis studyOsteoporos Int200819458158717924051
   PubMed Web of Science ®Google Scholar
• PatrickARBrookhartMALosinaEThe complex relation between bisphosphonate adherence and fracture reductionJ Clin Endocrinol Metab20109573251325920444916
   PubMed Web of Science ®Google Scholar
• ImazIZegarraPGonzalez-EnriquezJRubioBAlcazarRAmateJMPoor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysisOsteoporos Int201021111943195119967338
   PubMed Web of Science ®Google Scholar
• SambrookPNChenJSSimpsonJMMarchLMImpact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortalityMed J Aust2010193315415620678043
   PubMed Web of Science ®Google Scholar
• KawateHOhnakaKAdachiMAlendronate improves QOL of postmenopausal women with osteoporosisClin Interv Aging2010512313120458350
   PubMed Web of Science ®Google Scholar
• ChlebowskiRTChenZCauleyJAOral bisphosphonate use and breast cancer incidence in postmenopausal womenJ Clin Oncol201028223582359020567009
   PubMed Web of Science ®Google Scholar
• RennertGPinchevMRennertHSUse of bisphosphonates and risk of postmenopausal breast cancerJ Clin Oncol201028223577358120567021
   PubMed Web of Science ®Google Scholar
• BollandMJGreyABGambleGDReidIREffect of osteoporosis treatment on mortality: a meta-analysisJ Clin Endocrinol Metab20109531174118120080842
   PubMed Web of Science ®Google Scholar
• CreeMWJubyAGCarriereKCMortality and morbidity associated with osteoporosis drug treatment following hip fractureOsteoporos Int200314972272712904833
   PubMed Web of Science ®Google Scholar
• LylesKWColon-EmericCSMagazinerJSZoledronic acid in reducing clinical fracture and mortality after hip fractureN Engl J Med2007357 nihpa40967.
   PubMed Web of Science ®Google Scholar
• GehlbachSHAvruninJSPuleoETrends in hospital care for hip fracturesOsteoporos Int200718558559117146592
   PubMed Web of Science ®Google Scholar
• LeslieWDO’DonnellSJeanSTrends in hip fracture rates in CanadaJAMA2009302888388919706862
   PubMed Web of Science ®Google Scholar
• LofmanOBerglundKLarssonLTossGChanges in hip fracture epidemiology: redistribution between ages, genders and fracture typesOsteoporos Int2002131182511878451
   PubMed Web of Science ®Google Scholar
• ChevalleyTGuilleyEHerrmannFRHoffmeyerPRapinCHRizzoliRIncidence of hip fracture over a 10-year period 1991–2000 reversal of a secular trendBone20074051284128917292683
   PubMed Web of Science ®Google Scholar
• HaginoHKatagiriHOkanoTYamamotoKTeshimaRIncreasing incidence of hip fracture in Tottori Prefecture, Japan: trend from 1986 to 2001Osteoporos Int200516121963196816133645
   PubMed Web of Science ®Google Scholar
• IcksAHaastertBWildnerMBeckerCMeyerGTrend of hip fracture incidence in Germany 1995–2004 a population-based studyOsteoporos Int20081981139114518087659
   PubMed Web of Science ®Google Scholar
• LonnroosEKautiainenHKarppiPIncreased incidence of hip fractures. A population based-study in FinlandBone200639362362716603427
   PubMed Web of Science ®Google Scholar
• MannEIcksAHaastertBMeyerGHip fracture incidence in the elderly in Austria: an epidemiological study covering the years 1994 to 2006BMC Geriatr200883519105814
   PubMedGoogle Scholar
• DimaiHPSvedbomAFahrleitner-PammerAEpidemiology of hip fractures in Austria: evidence for a change in the secular trendOsteoporos Int2010511 [Epub ahead of print]
   Web of Science ®Google Scholar
• HernandezJLOlmosJMAlonsoMATrend in hip fracture epidemiology over a 14-year period in a Spanish populationOsteoporos Int200617346447016283063
   PubMed Web of Science ®Google Scholar
• KanisJAJohnellOOdenASmoking and fracture risk: a meta-analysisOsteoporos Int200516215516215175845
   PubMed Web of Science ®Google Scholar
• KannusPNiemiSParkkariJPalvanenMVuoriIJärvinenMNationwide decline in incidence of hip fractureJ Bone Miner Res200621121836183817002578
   PubMed Web of Science ®Google Scholar
• EnsrudKEBarrett-ConnorELSchwartzARandomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extensionJ Bone Miner Res20041981259126915231012
   PubMed Web of Science ®Google Scholar
• BlackDMSchwartzAVEnsrudKEEffects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trialJAMA2006296242927293817190893
   PubMed Web of Science ®Google Scholar